---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034239"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T21:39:50.684632+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026

## Summary
- Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.
- Cash, cash equivalents and investments $261.8M as of Dec 31, 2023; net cash used in ops $88.3M.
- Collaboration revenue from BMS agreement $2.2M in 2023, down from $5.2M in 2022.
- One-time impairment charge of $16.4M from consolidating facilities in Philadelphia and Seattle.
- FY2024 GAAP operating expense guidance $135M-$145M; cash runway expected into 2026.

## SEC filing metadata
- accession: 0001104659-24-034239
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/0001104659-24-034239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/tm248573d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034239
- JSON: https://secwatch.observer/filing/0001104659-24-034239.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034239.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: reported results
  source text: Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/0001104659-24-034239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.